A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for patients that are ineligible for, or resistant to these therapies. BH3 mimetics, drugs that mimic the act...
Saved in:
Main Authors: | Chiara R. Dart (Author), Nabanita Mukherjee (Author), Carol M. Amato (Author), Anabel Goulding (Author), Morgan MacBeth (Author), Robert Van Gulick (Author), Kasey L. Couts (Author), James R. Lambert (Author), David A. Norris (Author), William A. Robinson (Author), Yiqun G. Shellman (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010) -
Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
by: Ai Yoshioka, et al.
Published: (2017) -
A qualitative investigation into treatment regimen fatigue among people living with HIV
by: Kasey R. Claborn, et al.
Published: (2016) -
Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients
by: Paola Montes, et al.
Published: (2022) -
Knee Multiligament Reconstruction: ACL / PCL / MCL
by: Courtney Quinn MD, et al.
Published: (2022)